Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2025
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,657
-1.97%
|
$61,111
$23.59 P/Share
|
|
Jan 22
2025
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,195
-1.54%
|
$50,485
$23.59 P/Share
|
|
Jan 15
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,298
-0.35%
|
$55,152
$24.0 P/Share
|
|
Jan 15
2025
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,383
-0.16%
|
$57,192
$24.0 P/Share
|
|
Jan 15
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,767
-0.45%
|
$210,408
$24.0 P/Share
|
|
Jan 13
2025
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
16,845,010
+14.84%
|
$336,900,200
$20.0 P/Share
|
|
Jan 08
2025
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,105
-0.52%
|
$122,520
$24.1 P/Share
|
|
Jan 08
2025
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,105
-1.24%
|
$98,520
$24.1 P/Share
|
|
Dec 16
2024
|
Christopher Van Tuyl Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,956
+50.0%
|
-
|
|
Dec 02
2024
|
Douglas J. Hughes Director |
SELL
Open market or private sale
|
Direct |
5,425
-4.34%
|
$151,900
$28.54 P/Share
|
|
Dec 02
2024
|
Atul Pande Director |
SELL
Open market or private sale
|
Direct |
7,750
-8.21%
|
$217,000
$28.54 P/Share
|
|
Nov 20
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,174
-1.24%
|
$104,350
$25.45 P/Share
|
|
Nov 20
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,353
-0.92%
|
$83,825
$25.45 P/Share
|
|
Nov 20
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,650
-1.13%
|
$91,250
$25.45 P/Share
|
|
Nov 20
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,692
-1.68%
|
$417,300
$25.45 P/Share
|
|
Nov 18
2024
|
Melanie Gloria Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,956
+50.0%
|
-
|
|
Oct 23
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,361
-1.33%
|
$126,469
$29.53 P/Share
|
|
Oct 23
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,740
-1.89%
|
$79,460
$29.53 P/Share
|
|
Oct 23
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,189
-2.31%
|
$92,481
$29.53 P/Share
|
|
Oct 16
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,188
-0.43%
|
$89,264
$28.79 P/Share
|
|
Oct 16
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,095
-0.91%
|
$254,660
$28.79 P/Share
|
|
Oct 16
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,271
-0.97%
|
$91,588
$28.79 P/Share
|
|
Oct 16
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,860
-0.87%
|
$80,080
$28.79 P/Share
|
|
Oct 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,460
-0.44%
|
$129,340
$29.56 P/Share
|
|
Oct 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,162
-1.5%
|
$149,698
$29.56 P/Share
|
|
Aug 21
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,295
-0.49%
|
$105,440
$32.08 P/Share
|
|
Aug 21
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,027
-0.34%
|
$96,864
$32.08 P/Share
|
|
Aug 21
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,768
-0.54%
|
$120,576
$32.08 P/Share
|
|
Aug 21
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,027
-0.41%
|
$96,864
$32.08 P/Share
|
|
Aug 21
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,068
-0.74%
|
$482,176
$32.08 P/Share
|
|
Jul 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,456
-2.44%
|
$93,312
$27.76 P/Share
|
|
Jul 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,813
-1.9%
|
$75,951
$27.76 P/Share
|
|
Jul 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,015
-1.19%
|
$108,405
$27.76 P/Share
|
|
Jul 17
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,123
-0.45%
|
$93,690
$30.09 P/Share
|
|
Jul 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,044
-0.2%
|
$91,320
$30.09 P/Share
|
|
Jul 17
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,505
-0.37%
|
$75,150
$30.09 P/Share
|
|
Jul 17
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,685
-0.42%
|
$260,550
$30.09 P/Share
|
|
Jul 17
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,867
-0.32%
|
$86,010
$30.09 P/Share
|
|
Jul 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,619
-0.45%
|
$129,332
$28.06 P/Share
|
|
Jul 09
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,527
-0.34%
|
$42,756
$28.06 P/Share
|
|
Jul 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,747
-1.34%
|
$132,916
$28.06 P/Share
|
|
May 22
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.72%
|
$94,163
$29.65 P/Share
|
|
May 22
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,163
-1.54%
|
$468,727
$29.65 P/Share
|
|
May 22
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,042
-1.12%
|
$117,218
$29.65 P/Share
|
|
May 22
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,242
-0.94%
|
$94,018
$29.65 P/Share
|
|
May 22
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.86%
|
$94,163
$29.65 P/Share
|
|
Apr 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,239
-4.67%
|
$202,692
$28.9 P/Share
|
|
Apr 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,261
-2.25%
|
$91,308
$28.9 P/Share
|
|
Apr 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,963
-1.14%
|
$110,964
$28.9 P/Share
|
|
Apr 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,280
-0.54%
|
$240,120
$29.37 P/Share
|